AU2022231038A1 - Treatment of copper disorders - Google Patents

Treatment of copper disorders Download PDF

Info

Publication number
AU2022231038A1
AU2022231038A1 AU2022231038A AU2022231038A AU2022231038A1 AU 2022231038 A1 AU2022231038 A1 AU 2022231038A1 AU 2022231038 A AU2022231038 A AU 2022231038A AU 2022231038 A AU2022231038 A AU 2022231038A AU 2022231038 A1 AU2022231038 A1 AU 2022231038A1
Authority
AU
Australia
Prior art keywords
copper
triethylenetetramine disuccinate
triethylenetetramine
dose
article
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022231038A
Other languages
English (en)
Inventor
Garth Cooper
Margaret Cooper
Joseph Fortunak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHILERA NEW ZEALAND Ltd
Original Assignee
PHILERA NEW ZEALAND Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHILERA NEW ZEALAND Ltd filed Critical PHILERA NEW ZEALAND Ltd
Publication of AU2022231038A1 publication Critical patent/AU2022231038A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Conductive Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022231038A 2021-03-05 2022-03-04 Treatment of copper disorders Pending AU2022231038A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163157539P 2021-03-05 2021-03-05
US63/157,539 2021-03-05
PCT/US2022/019025 WO2022187709A1 (en) 2021-03-05 2022-03-04 Treatment of copper disorders

Publications (1)

Publication Number Publication Date
AU2022231038A1 true AU2022231038A1 (en) 2023-09-21

Family

ID=83115853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022231038A Pending AU2022231038A1 (en) 2021-03-05 2022-03-04 Treatment of copper disorders

Country Status (7)

Country Link
US (2) US20220280451A1 (https=)
EP (1) EP4301350A4 (https=)
JP (1) JP2024509193A (https=)
CN (1) CN117157064A (https=)
AU (1) AU2022231038A1 (https=)
CA (1) CA3212016A1 (https=)
WO (1) WO2022187709A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023255339A1 (en) * 2022-04-19 2024-12-05 Sasha A. PHILBERT Treatment of brain copper disorders
CN118987254A (zh) * 2024-08-15 2024-11-22 沈阳药科大学 一种基于双金属纳米点-溶瘤病毒静脉递送系统及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875522A1 (en) * 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
PT1778618E (pt) * 2004-07-19 2014-03-04 Philera New Zealand Ltd Síntese de trietilenotetraminas
WO2006104396A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Pre-complexed copper antagonist compositions
CA3018698A1 (en) * 2005-11-09 2007-05-18 Philera New Zealand Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
US20090093542A1 (en) * 2007-10-04 2009-04-09 Cooper Garth J S Copper antagonist compositions
WO2017049529A1 (en) * 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
WO2017213524A1 (en) * 2016-06-10 2017-12-14 Garth Cooper Treatment of neurodegenerative disorders
CA3143523A1 (en) * 2019-06-17 2020-12-24 Philera New Zealand Ltd. Combination treatments for central nervous system disorders

Also Published As

Publication number Publication date
US20250114312A1 (en) 2025-04-10
EP4301350A4 (en) 2025-04-09
WO2022187709A1 (en) 2022-09-09
CA3212016A1 (en) 2022-09-09
JP2024509193A (ja) 2024-02-29
US20220280451A1 (en) 2022-09-08
CN117157064A (zh) 2023-12-01
EP4301350A1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
US20250114312A1 (en) Treatment of copper disorders
US9925158B2 (en) Enterically coated cysteamine, cystamine and derivatives thereof
Hemauer et al. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin
CN104284665B (zh) 吡唑衍生物及其医药用途
JP6067203B2 (ja) ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用
EP3288561B1 (en) Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
CN111050764A (zh) β-羟基丁酸酯和丁二醇的S对映异构体及其使用方法
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
JP2025066802A (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
US20200263184A1 (en) Pharmaceutical composition for preventing and treating cancer, containing malate-aspartate shuttle inhibitor and anticancer drug as active ingredients
Cappellini et al. Iron overload
CN109310685A (zh) 用于治疗癌症的notch和pi3k/mtor抑制剂的组合疗法
EP4445914A1 (en) Pharmaceutical composition for treating tumors and use
CA2998730A1 (en) Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
EP3242723B1 (en) Use of hinokitiol for restoring physiology in iron-deficient organisms
JP2006513223A (ja) ｐ−アミノ安息香酸（ＰＡＢＡ）によるメラニン形成及びメラノーマ転移の阻害
CN101534840A (zh) 治疗放射性肠炎的方法
ES2689906T3 (es) Meglumina para reducir los niveles altos de triglicéridos
Smith Drugs and pharmaceuticals: management of intoxication and antidotes
CN113476432B (zh) J147在制备治疗和/或预防色素增多性疾病的药物/化妆品的用途
Choudhary et al. Comparison of renal functions evaluated by measured glomerular filtration rate in patients treated with cisplatin, carboplatin, and oxaliplatin
WO2020192506A1 (zh) 西奥罗尼用于小细胞肺癌的治疗
CN117327067A (zh) 一种小分子化合物epic-1042、药物组合物及其制备方法和应用
Eldalal et al. The Correlation between Pharmacological Param-eters of Oxycodone and Opioid Epidemic
Malhotra et al. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing